Tianhui Hu

Find an error

Name:
Organization: Xiamen University
Department: Cancer Research Center
Title:
Co-reporter:Fen Lin;Wei Yan;Gang Song;Wen Ting;Guoyang Wu
Science Bulletin 2014 Volume 59( Issue 28) pp:3585-3594
Publication Date(Web):2014 October
DOI:10.1007/s11434-014-0468-2
Liver tumor-initiating cells (T-ICs) are thought to be inherently resistant to the cytotoxic effects of chemotherapy, and can self-renewal and maintain tumor-initiating potential. Therefore, effective anticancer research strategies should target the unique properties of T-ICs. In this study, we found that metformin, a first-line drug of choice for the treatment of type 2 diabetes, inhibited liver T-ICs both in vivo and in vitro. Metformin inhibited the formation of hepatospheres and epithelial-specific antigen-positive (ESA, CD133+) cell colonies by hepatocellular carcinoma (HCC) cell lines. Metformin also downregulated the expression of several T-IC-related genes which are involved in the signaling pathways, governing the self-renewal, proliferation and differentiation of T-ICs. Furthermore, the targeting of liver T-ICs by metformin was PI-3-kinase-Akt-mTOR (PI3K/Akt/mTOR)-pathway dependent. The PI3K/Akt/mTOR inhibitor LY294002 and rapamycin abolished the inhibitory effect of metformin on CD133+ cells, and the PI3K/Akt/mTOR stimulator EGF promoted the inhibitory effect of metformin on CD133+ cells. Metformin also dramatically decreased the tumor volume and number of CD133 expressing tumor cells in a xenograft mouse model. Metformin exerted a synergistic effect with cisplatin to target both T-ICs and non-T-ICs, and resulted in the smallest tumor volume and lowest number of CD133 expressing tumor cells. This study indicates that the antidiabetic drug metformin could potentially be used in combination therapy with chemotherapeutic agents to improve the treatment of liver cancer.
Co-reporter:Junfang Zhang;Hailong Cao;Bing Zhang;Hanwei Cao;Xiuqin Xu;Hang Ruan;Tingting Yi;Li Tan;Rui Qu;Gang Song;Bangmao Wang
Journal of Cellular and Molecular Medicine 2013 Volume 17( Issue 11) pp:1484-1493
Publication Date(Web):
DOI:10.1111/jcmm.12119

Abstract

As a traditional anti-inflammatory Chinese herbal medicine, Alkaloid berberine has been recently reported to exhibit anti-tumour effects against a wide spectrum of cancer. However, the mechanism was largely unknown. Gene chip array reveals that with berberine treatment, c-Myc, the target gene of Wnt pathway, was down-regulated 5.3-folds, indicating that berberine might inhibit Wnt signalling. TOPflash analysis revealed that Wnt activity was significantly reduced after berberine treatment, and the mechanism of which might be that berberine disrupted β-catenin transfer to nucleus through up-regulating the expression of adenomatous polyposis coli (APC) gene and stabilized APC-β-catenin complex. Berberine administration in ApcMin/+ mice exhibited fewer and smaller polyps in intestine, along with reduction in cyclin D1 and c-Myc expression. In clinical practice, oral administration of berberine also significantly reduced the familial adenomatous polyposis patients' polyp size along with the inhibition of cyclin D1 expression in polyp samples. These observations indicate that berberine inhibits colon tumour formation through inhibition of Wnt/β-catenin signalling and berberine might be a promising drug for the prevention of colon cancer.

Co-reporter:Chun Hu;Gang Song;Bing Zhang;Zhongchen Liu;Rong Chen;Hong Zhang
Journal of Cellular and Molecular Medicine 2012 Volume 16( Issue 1) pp:96-106
Publication Date(Web):
DOI:10.1111/j.1582-4934.2011.01278.x

Abstract

Compound K (20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol, CK), an intestinal bacterial metabolite of panaxoside, has been shown to inhibit tumour growth in a variety of tumours. However, the mechanisms involved are largely unknown. We use human gastric carcinoma cell lines BGC823, SGC7901 and human gastric carcinoma xenograft in nude mice as models to study the mechanisms of CK in gastric cancers. We found that CK significantly inhibits the viabilities of BGC823 and SGC7901 cells in dose- and time-dependent manners. CK-induced BGC823 and SGC7901 cells apoptosis and cell cycle arrest in G2 phase by up-regulation of p21 and down-regulation of cdc2 and cyclin B1. Further studies show that CK induces apoptosis in BGC823 and SGC7901 cells mainly through mitochondria-mediated internal pathway, and that CK induces the translocation of nuclear Bid to mitochondria. Finally, we found that CK effectively inhibited the tumour formation of SGC7901 cells in nude mice. Our studies show that CK can inhibit the viabilities and induce apoptosis of human gastric carcinoma cells via Bid-mediated mitochondrial pathway.

Co-reporter:Tianhui Hu;Zhaoxia Liu;Xun Shen
Journal of Cellular and Molecular Medicine 2011 Volume 15( Issue 3) pp:647-653
Publication Date(Web):
DOI:10.1111/j.1582-4934.2010.01035.x

Abstract

The phorbol myristate acetate (PMA) stimulated nutrophil respiratory burst has been considered to simply involve the activation of protein kinase C (PKC). However, the PLD activity was also increased by 10-fold in human neutrophils stimulated with 100 nM PMA. Unexpectedly, U73122, an inhibitor of phospholipase C, was found to significantly inhibit PMA-stimulated respiratory burst in human neutrophils. U73122 at the concentrations, which were sufficient to inhibit the respiratory burst completely, caused partial inhibition of the PLD activity but no inhibition on PKC translocation and activation, suggesting that PLD activity is also required in PMA-stimulated respiratory burst. Using 1-butanol, a PLD substrate, to block phosphatidic acid (PA) generation, the PMA-stimulated neutrophil respiratory burst was also partially inhibited, further indicating that PLD activation, possibly its hydrolytic product PA and diacylglycerol (DAG), is involved in PMA-stimulated respiratory burst. Since GF109203X, an inhibitor of PKC that could completely inhibit the respiratory burst in PMA-stimulated neutrophils, also caused certain suppression of PLD activation, it may suggest that PLD activation in PMA-stimulated neutrophils might be, to some extent, PKC dependent. To further study whether PLD contributes to the PMA stimulated respiratory burst through itself or its hydrolytic product, 1,2-dioctanoyl-sn-glycerol, an analogue of DAG , was used to prime cells at low concentration, and it reversed the inhibition of PMA-stimulated respiratory burst by U73122. The results indicate that U73122 may act as an inhibitor of PLD, and PLD activation is required in PMA-stimulated respiratory burst.

Co-reporter:Gang Song, Shiguang Guo, Weiwei Wang, Chun Hu, Yubing Mao, Bing Zhang, Hong Zhang, and Tianhui Hu
Journal of Agricultural and Food Chemistry 2010 Volume 58(Issue 24) pp:12753-12760
Publication Date(Web):December 1, 2010
DOI:10.1021/jf103814f
It was recently shown that compound K (CK), an intestinal bacterial metabolite of ginseng saponin, exhibits antihepatocellular carcinoma (HCC) activity, and Bid is a potential drug target for HCC therapy. This paper reports a novel mechanism of CK-induced apoptosis of HCC cells via Bid-mediated mitochondrial pathway. CK dramatically inhibited HCC cells growth in concentration- and time-dependent manners, and a high dose of CK could induce HCC cell apoptotic cell death. Furthermore, the effective dose of CK potently attenuated the subcutaneous tumor growth and spontaneous HCC metastasis in vivo. At the molecular level, immunohistochemical staining revealed that Bid expression in subcutaneous tumor and liver metastasis tissues decreased dramatically in CK-treated groups compared to untreated controls, which also implies that Bid may play a critical role in the growth and progression of HCC. Further study shows that translocation of full-length Bid to the mitochondria from nuclei during cytotoxic apoptosis was associated with the release of cytochrome c from mitochondria, indicating that full-length Bid is sufficient for the activation of mitochondrial cell death pathways in response to CK treatment in HCC cells. Taken together, the results not only reveal a Bid-mediated mitochondrial pathway in HCC cells induced by CK but also suggest that CK may become a potential cytotoxic drug targeting Bid in the prevention and treatment of HCC.
Co-reporter:Gang Song;Gaoliang Ouyang;Yubin Mao;Yanlin Ming;Shideng Bao
Journal of Cellular and Molecular Medicine 2009 Volume 13( Issue 8b) pp:1706-1718
Publication Date(Web):
DOI:10.1111/j.1582-4934.2008.00540.x

Abstract

Osteopontin (OPN) is a secreted, integrin-binding matrix phosphorylated glycoprotein. OPN has been shown to facilitate the progression and metastasis of malignancies and has prognostic value in several types of cancer, including gastric cancer. However, the functional mechanism of OPN mediated metastatic growth in gastric cancer remains unclear. Here, using multiple in vitro and in vivo models, we report that OPN strongly promoted the progression and metastasis of gastric cancer. Immunohistochemical staining revealed that OPN, matrix metalloproteinase (MMP)9 and hypoxia-inducible factor (HIF)-1α have statistically significant different expression patterns between well- and poorly differentiated tissue samples (P < 0.05). Correlations existed between OPN and MMP9, and between OPN and HIF-1α (r1= 0.872, p1 < 0.01 and r2= 0.878, p2 < 0.01). Furthermore, OPN dramatically increased colony formation and invasion of gastric cancer cells in vitro and promoted tumour growth and metastasis in vivo. In addition, OPN potently protected gastric cancer cells from serum depletion-induced apoptosis. Further study shows that OPN activated phosphoinositide 3-kinase/Akt survival pathway and up-regulated HIF-1αvia binding to αvβ3 integrins in gastric cancer cells. Moreover, we found that OPN could activate MMP9 and up-regulate MMP2. Taken together, our results suggest that the survival-promoting function is crucial for OPN to promote the development of gastric cancer, and HIF-1α and MMP9 may play key roles during this process. Thus, targeting OPN and its related signalling network may develop an effective therapeutic approach for the management of gastric cancer.

(-)-jiadifenolide
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride
Phosphatidylinositol 3-kinase
CYCLOPENTANECARBOXYLIC ACID, 2-METHYL-5-OXO-, ETHYL ESTER, (2R)-
3,6-diamino-9-[2-(methoxycarbonyl)phenyl]xanthylium chloride
Ginsenoside Rb1
Cyclohexaneacetaldehyde, 1-hydroxy-
(20S)-20-(WEI -D-GLUCOPYRANOSYLOXY)DAMMARA-24-ENE-3WEI ,12WEI -DIOL